The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.
Adults 18 to 75 years of age.
Able to provide informed consent.
Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition.
Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment.
Chronic pain condition that requires ongoing pain medication.
Significant medical or psychiatric condition that could affect participation or study results.
History of substance use disorder or misuse of alcohol or drugs.
Current use of medications that may interfere with the study drug or pain assessments.
Single group
Cebranopadol 400 ug
DrugParticipants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.
Sum of pain intensity differences through 48 hours (SPID48)
Sum of pain intensity differences through 48 hours (SPID48), calculated from NPRS assessments collected following the first administration of cebranopadol.
Click on the lead sponsor to view all of their trials.
